6-[(5-Fluoro-2,4-dioxopyrimidin-1-yl)methoxy]-6-oxohexanoic acid | 201210-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-[(5-Fluoro-2,4-dioxopyrimidin-1-yl)methoxy]-6-oxohexanoic acid
• CAS: 201210-73-3
• 化学式: C₁₁H₁₃FN₂O₆
• 分子量: 288.232
• InChiKey: WRFZOBHAZYVZRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-[(5-Fluoro-2,4-dioxopyrimidin-1-yl)methoxy]-6-oxohexanoic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 98.0h， 生成 (5-fluoro-2,4-dioxopyrimidin-1-yl)methyl 6-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-6-oxohexanoate
  参考文献：
  名称：

  Synthesis and Reactivity of 5-Fluorouracil/Cytarabine Mutual Prodrugs

  摘要：

  Two mutual prodrugs, in which two different anti-cancer drugs are attached to the same molecule via labile linkages, are synthesized and examined kinetically. One of the mutual prodrugs loses a drug component under physiological conditions within an hour, but the other mutual prodrug (having a longer spacer between the two drugs) is stable to chemical degradation even at higher pH values. Thus, enzymatic hydrolysis alone will release the two anti-cancer drugs. The potential value of anti-cancer mutual prodrugs is discussed.

  DOI：

  10.1021/jo971076p
• 作为产物：
  描述：

  己二酸单苄酯 在 palladium on activated charcoal 磺酰氯 、 1,4-环己二烯 、 cis-1,2,3,6-tetrahydrophthalic acid 、 caesium carbonate 、 三乙胺 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.0h， 生成 6-[(5-Fluoro-2,4-dioxopyrimidin-1-yl)methoxy]-6-oxohexanoic acid
  参考文献：
  名称：

  Synthesis and Reactivity of 5-Fluorouracil/Cytarabine Mutual Prodrugs

  摘要：

  Two mutual prodrugs, in which two different anti-cancer drugs are attached to the same molecule via labile linkages, are synthesized and examined kinetically. One of the mutual prodrugs loses a drug component under physiological conditions within an hour, but the other mutual prodrug (having a longer spacer between the two drugs) is stable to chemical degradation even at higher pH values. Thus, enzymatic hydrolysis alone will release the two anti-cancer drugs. The potential value of anti-cancer mutual prodrugs is discussed.

  DOI：

  10.1021/jo971076p

文献信息

• Synthesis and Characterization of New Liver Targeting 5-Fluorouracil-Cholic Acid Conjugates
  作者：Shan Qian、Jian-Bo Wu、Xiao-Chun Wu、Jie Li、Yong Wu

  DOI：10.1002/ardp.200900075

  日期：2009.9

  of this work was to develop a liver‐specific antihepato carcinoma agent. A series of 5‐fluorouracil / cholic acid conjugates (5‐FU‐cholic acid conjugates) were prepared and tested for their chemical characteristics and bio‐distribution properties. The in‐vitro stability trial showed 5‐FU‐cholic acid conjugates could be completely hydrolyzed by heating at 70°C in an acidic solution, pH = 1, for 5 min

  这项工作的目的是开发一种肝脏特异性抗肝癌药物。制备了一系列 5-氟尿嘧啶/胆酸结合物（5-FU-胆酸结合物）并测试了它们的化学特性和生物分布特性。体外稳定性试验表明，5-FU-胆酸结合物可以通过在 70°C、pH = 1 的酸性溶液中加热 5 分钟来完全水解。这些化合物的快速完全水解可以与快速分离和分析方法兼容，以缩短分析时间。通过测量器官组织中再生 5-FU 的浓度来评估口服给药后几个时间点 5-FU-胆酸结合物在小鼠不同器官中的分解速度。将结果与对照组的结果进行比较，这是一组口服 5-FU 的小鼠。口服前药后，小鼠肝组织中 5-FU 的浓度显着升高，远高于仅口服 5-FU 时的浓度。结果表明，以胆酸为药物载体，提高肝脏靶向治疗疗效的可行性。
• 靶向MCT1转运体的5-氟尿嘧啶成酯前药
  申请人：沈阳药科大学

  公开号：CN109761915B

  公开（公告）日：2021-12-21

  本发明属于医药领域，涉及靶向MCT1转运体的5‑氟尿嘧啶成酯前药，具体涉及包括不同碳链长度的含有单羧酸酯的5‑氟尿嘧啶口服前药的合成，以及其在药物传递和治疗中的应用。本发明设计合成了不同碳链长度含有单羧酸酯的5‑氟尿嘧啶口服前药，将该前药用于靶向MCT1转运体，从而实现稳定性好、毒副作用低、渗透性高和口服生物利用度高的效果。同时，以不含羧酸的成酯前药作为对照，考察含有或不含有单羧酸的前药在化学性质以及体内外实验等方面的差异，以及前药是否能通过靶向MCT1转运体进而改善原有5‑氟尿嘧啶渗透性差以及口服生物利用度低的缺点。得到了最佳的口服前药，满足临床中对口服制剂的迫切需求。
• Development of 5-fluorouracil-dichloroacetate mutual prodrugs as anticancer agents
  作者：Ewa Mironiuk-Puchalska、Olena Karatsai、Agnieszka Żuchowska、Wojciech Wróblewski、Filip Borys、Lilya Lehka、Maria Jolanta Rędowicz、Mariola Koszytkowska-Stawińska

  DOI：10.1016/j.bioorg.2023.106784

  日期：2023.11
• Synthesis and Reactivity of 5-Fluorouracil/Cytarabine Mutual Prodrugs
  作者：Fredric M. Menger、Michael J. Rourk

  DOI：10.1021/jo971076p

  日期：1997.12.1

  Two mutual prodrugs, in which two different anti-cancer drugs are attached to the same molecule via labile linkages, are synthesized and examined kinetically. One of the mutual prodrugs loses a drug component under physiological conditions within an hour, but the other mutual prodrug (having a longer spacer between the two drugs) is stable to chemical degradation even at higher pH values. Thus, enzymatic hydrolysis alone will release the two anti-cancer drugs. The potential value of anti-cancer mutual prodrugs is discussed.